EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus

  • Licensing deal grants EsoCap exclusive access to Upadia’s monoclonal antibodies for a local therapy for Barrett’s esophagus
  • Barrett’s esophagus, a disease of the esophagus with high unmet medical need, affects 1-2% of the population, with the risk of evolving into esophageal cancer
  • EsoCap to combine its unique targeted application technology for the upper gastrointestinal tract with Upadia antibodies to develop new treatment approach to this highly prevalent disease

EsoCap, the Swiss biotech company dedicated to improving the lives of patients with serious diseases of the upper gastrointestinal tract, announced today that the company has entered into a worldwide, exclusive antibody licensingagreement with Upadia, to develop targeted therapeutics to treat Barrett’s esophagus (BE).

Under the terms of the agreement, Upadia will provide an exclusive licence for its range of highly specific monoclonal antibodies, so EsoCap can develop therapies against BE using EsoCap’s unique, proprietary targeted application technology for the upper gastrointestinal (GI) tract. The EsoCap technology offers maximum flexibility, as a wide variety of drug substances, including biologics, can be incorporated into the thin film, making the smart drug delivery platform applicable to many different upper GI diseases.

Read full PDF